Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021
- Corporate and Finance
Jul 6, 2021
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
- COVID-19
Jun 30, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021
- Statement
- COVID-19
Jun 30, 2021
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
- Statement
- COVID-19
Jun 22, 2021
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
- Corporate and Finance
Jun 17, 2021
Novavax to Participate in National Vaccine Advisory Committee Meeting
- Corporate and Finance
Jun 17, 2021
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
- COVID-19
- Seasonal Influenza
Jun 14, 2021
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
- COVID-19
Jun 14, 2021
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
- COVID-19
Jun 11, 2021
Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters
- Corporate and Finance
Jun 9, 2021

Show per page